Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
2(20%)
Results Posted
33%(2 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_2
5
50%
Ph phase_1
1
10%
Ph phase_3
4
40%

Phase Distribution

1

Early Stage

5

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
4(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 25 (50.0%)
Phase 34 (40.0%)

Trials by Status

completed660%
active_not_recruiting110%
recruiting110%
terminated220%

Recent Activity

2 active trials
Showing 5 of 10
active_not_recruitingphase_2

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

NCT01786265
completedphase_2

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

NCT03070886
recruitingphase_3

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

NCT03678025
completedphase_3

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

NCT00003653
completedphase_3

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

NCT00002633
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01786265Phase 2

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Active Not Recruiting
NCT03070886Phase 2

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Completed
NCT03678025Phase 3

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting
NCT00003653Phase 3

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Completed
NCT00002633Phase 3

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Completed
NCT00002855Phase 3

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

Completed
NCT00020254Phase 2

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

Completed
NCT00918385Phase 2

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Terminated
NCT00028769Phase 2

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Completed
NCT00512668Phase 1

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

Terminated

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10